GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (OSTO:BIOSGN) » Definitions » Additional Paid-In Capital

Biosergen AB (OSTO:BIOSGN) Additional Paid-In Capital : kr0.00 Mil(As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB Additional Paid-In Capital?


Biosergen AB Additional Paid-In Capital Historical Data

The historical data trend for Biosergen AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosergen AB Additional Paid-In Capital Chart

Biosergen AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
- - - - -

Biosergen AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biosergen AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Biosergen AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Biosergen AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosergen AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (OSTO:BIOSGN) » Definitions » Additional Paid-In Capital
Comparable Companies
XSAT:ABERA XSAT:BIOWKS OSTO:KAN XSAT:DEX OSTO:ALZ OSTO:NICA OSTO:PILA NGM:GTAB B OSTO:SPAGO OSTO:ISOFOL VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Fogdevreten 2, Solna, SWE, 17165
Website
https://www.biosergen.net
Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen' s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.

Biosergen AB Headlines

No Headlines